Eli Lilly says its drug cuts COVID risk in nursing homes

About This Source - Reuters

Reuters is an international news organization owned by Thomson Reuters. It employs some 2,500 journalists and 600 photojournalists in about 200 locations worldwide. The agency was established in London in 1851 by the German-born Paul Reuter.

Recent from Reuters:

  • Australia to hold inquiry into military suicides
  • Flights land in New Zealand-Australia travel bubble
  • Caribbean island rocked by volcanic eruptions
  • Reuters published this video item, entitled “Eli Lilly says its drug cuts COVID risk in nursing homes” – below is their description.

    Drugmaker Eli Lilly said a trial of its antibody drug, bamlanivimab, showed it can reduce the risk of COVID-19 by 80% for nursing home residents.

    Reuters YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    In This Story: COVID-19

    Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.

    Symptoms of coronavirus

    The main symptoms of coronavirus are:

    • a persistent new cough (non productive, dry)
    • a high temperature (e.g. head feels warm to the touch)
    • shortness of breath (if this is abnormal for the individual, or increased)

    Latest News about Covid-19

    Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.

    5 Recent Items: COVID-19

  • Honouring ageing Queensland soldiers this Anzac Day | 7NEWS
  • South Korea braces for possible fourth coronavirus wave amid slow vaccination drive
  • Coronavirus: Families reunite as Trans-Tasman bubble begins | 9 News Australia
  • Cape Verde governing party retains power after winning parliamentary polls
  • Coronavirus: Australians over 50 to receive COVID-19 jab | 9 News Australia
  • Leave a Comment